Temozolomide promotes genomic and phenotypic changes in glioblastoma cells

Table 1 Long-term TMZ treatment of tumour cells results in versatile phenotype responses

Cell line	Morphology	Proliferation/viability	Cell cycle distribution	Migration/invasion	Growth in vivo/soft agar	Concentration/treatment period	Refs
A172	No change					100 μM/1 mo	[62]
C6	No change	↓		↓	↓ in soft agar	100 μM/1 mo in vitro or 50 mg/kg/10 injections in vivo	this study
D54	Changed	↓	↑ G0/G1 ↓ G2/M	↑		up to 0.5 mM/ 5 or 10 mo	[14]
CSC		↓			↓ in vivo		[10]
HEK293 derivatives	No change	↓			↓ in soft agar	up to 120 μM/ 3 mo	[23]
HeLa derivatives	No change	No change or ↑			↑ in soft agar	up to 120 μM/ 3 mo	[23]
Hs683		↓		↓	↓ in vivo	up to 1 mM/ 10 mo	[8]
LN-308, LNT-229, LN-18	No change	↓	No change			up to EC₅₀/6 mo	[7]
T98G		↓		No change	No change in vivo	up to 1 mM	[19]
T98G	No change	No change		No change	↑ in soft agar	100 μM/1 mo	this study
U87	Changed			↑		up to IC₅₀ = 150 µM/3 weeks	[18]
U251			↑ G2/M				[21]
U251	No change	↓ or ↑		↓ or ↑	No change in soft agar	up to 100 μM/ 5 or 10 weeks	this study
U373		↑		↑	↑ in vivo	up to 1 mM	[19]

ISSN: 1475-2867